Literature DB >> 8781879

Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

E González-Barca1, A Fernández-Sevilla, J Carratalá, A Grañena, F Gudiol.   

Abstract

Trends in causative organisms and sources of infection were studied in a series of 288 episodes of bacteremia in neutropenic cancer patients observed in a single institution from 1986 to 1993. The incidence of bacteremia increased significantly from 20 episodes per 1000 admissions in 1986 to 50 episodes per 1000 admissions in 1993 (p = 0.00001). Over the study period, a continuous increment in gram-positive bacteremia, which reached 81% of episodes in 1993 (p = 0.000001), was observed. Conversely, the incidence of gram-negative bacteremia remained stable. Coagulase-negative staphylococci and viridans group streptococci were the most commonly isolated pathogens. Bacteremia caused by coagulase-negative staphylococci increased from 3 episodes per 1000 admissions to 19 episodes per 1000 admissions (p = 0.0001), and viridans group streptococci bacteremia increased from 0 episodes per 1000 admissions to 19 episodes per 1000 admissions (p = 0.000001). The upward trend in gram-positive bacteremia appeared to be related to a significant increase in both intravascular catheters (p = 0.003) and oral mucositis (p = 0.003) as sources of infection. Specific strategies to prevent chemotherapy-induced mucositis and catheter-related bacteremia merit further investigations.

Entities:  

Mesh:

Year:  1996        PMID: 8781879     DOI: 10.1007/bf01695660

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

1.  Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

Authors:  A Cometta; T Calandra; J Bille; M P Glauser
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

2.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

3.  Gram-positive bacteraemia in granulocytopenic cancer patients.

Authors: 
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

4.  Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.

Authors:  J Carratalá; F Alcaide; A Fernández-Sevilla; X Corbella; J Lińares; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

5.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

6.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

7.  Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy.

Authors:  D J Winston; D V Dudnick; M Chapin; W G Ho; R P Gale; W J Martin
Journal:  Arch Intern Med       Date:  1983-01

8.  Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.

Authors:  E J Bow; E Rayner; T J Louie
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

9.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more
  24 in total

1.  Streptococcus gordonii biofilm formation: identification of genes that code for biofilm phenotypes.

Authors:  C Y Loo; D A Corliss; N Ganeshkumar
Journal:  J Bacteriol       Date:  2000-03       Impact factor: 3.490

2.  In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.

Authors:  F Alcaide; M A Benítez; J Carratalà; F Gudiol; J Liñares; R Martín
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 3.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

4.  The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies.

Authors:  Y-K Chen; H-A Hou; J-M Chow; Y-C Chen; P-R Hsueh; H-F Tien
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

5.  Involvement of the adc operon and manganese homeostasis in Streptococcus gordonii biofilm formation.

Authors:  C Y Loo; K Mitrakul; I B Voss; C V Hughes; N Ganeshkumar
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

6.  Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis?

Authors:  Sonja Lüer; Rolf Troller; Marion Jetter; Violeta Spaniol; Christoph Aebi
Journal:  Support Care Cancer       Date:  2010-05-14       Impact factor: 3.603

7.  Ralstonia pickettii bloodstream infections at a Brazilian cancer institution.

Authors:  Flávia L P C Pellegrino; Marcelo Schirmer; Eduardo Velasco; Lúcia M de Faria; Kátia R N Santos; Beatriz Meurer Moreira
Journal:  Curr Microbiol       Date:  2007-11-10       Impact factor: 2.188

8.  Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center.

Authors:  E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

9.  The effectiveness of an oral health education and prevention program on the incidence and severity of oral mucositis in pediatric cancer patients: a non-randomized controlled study.

Authors:  Paula Maria Maracajá Bezerra; Maria Eduarda Alves Sampaio; Fabio Gomes Dos Santos; Isabella Lima Arrais Ribeiro; Bianca Marques Santiago; Simone Alves de Sousa; Ana Maria Gondim Valença
Journal:  Support Care Cancer       Date:  2021-06-29       Impact factor: 3.603

10.  Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern.

Authors:  Patrick G Morris; Tidi Hassan; Mairead McNamara; Astrid Hassan; Rebecca Wiig; Liam Grogan; Oscar S Breathnach; Edmond Smyth; Hilary Humphreys
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.